SCHEMBL2179050

SCHEMBL2179050

CCCCCCCCc1ccc(C(=O)Nc2ccc(-c3ccc4c(c3)C(=O)N(C(C(=O)O)C(C)C)C4)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 8/20 0.44
ITGB3 P05106 2/20 0.43
ITGA2B P08514 2/20 0.43
ITGA2 P17301 2/20 0.43
KDM4E B2RXH2 2/20 0.43
RARB P10826 4/20 0.41
MAPT P10636 2/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
RARA P10276 1/20 0.41
MTOR P42345 1/20 0.41
KMT2A Q03164 1/20 0.41
SDCBP O00560 2/20 0.41
SDC2 P34741 2/20 0.41
TP53 P04637 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPC1 O15118 1/20 0.40
GALR3 O60755 1/20 0.40
RAB9A P51151 1/20 0.40
PLK1 P53350 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13719146 1.00 TRPV1 (0.44) TRPV1ITGB3ITGA2BITGA2KDM4E
SCHEMBL13718911 1.00 TRPV1 (0.44) TRPV1ITGB3ITGA2BITGA2KDM4E
SCHEMBL13719354 1.00 TRPV1 (0.44) TRPV1ITGB3ITGA2BITGA2KDM4E
SCHEMBL2181350 1.00 TRPV1 (0.44) TRPV1ITGB3ITGA2BITGA2KDM4E
SCHEMBL2178747 1.00 TRPV1 (0.44) TRPV1ITGB3ITGA2BITGA2KDM4E
SCHEMBL2180558 1.00 TRPV1 (0.44) TRPV1ITGB3ITGA2BITGA2KDM4E
SCHEMBL13718568 1.00 TRPV1 (0.44) TRPV1ITGB3ITGA2BITGA2KDM4E
SCHEMBL13719202 1.00 TRPV1 (0.44) TRPV1ITGB3ITGA2BITGA2KDM4E
SCHEMBL2178074 1.00 TRPV1 (0.44) TRPV1ITGB3ITGA2BITGA2KDM4E
SCHEMBL2179559 0.99 TRPV1 (0.44) TRPV1ITGB3ITGA2BITGA2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT TRPV1 2047/4885ITGB3 4621/4885ITGA2B 4607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.